Genomadix Bioscience Names Nick Noreau as Chief Revenue Officer

04/09/2019

Genomadix Bioscience today announced that Nick Noreau has been named Chief Revenue Officer. Mr. Noreau will lead revenue growth and market expansion for Genomadix’s DNA diagnostic devices and tests.

Mr. Noreau has more than 20 years of global sales experience at technology and healthcare companies. He joins Genomadix from Nuance Communications (NASQAD:NUAN), where he served as Regional Vice President of Healthcare Sales. In 2016, Mr. Noreau led an acquisition for Nuance and grew the division’s revenues from $30 million to $72 million in two years. Previously, Mr. Noreau held senior leadership roles at Veritaaq, Taima (acquired by Convergys), and Accentus (acquired by Nuance).

“Nick’s proven ability to scale companies from startup to major revenues will play a key role in Genomadix’s continued growth,” said Paul Lem, M.D., CEO of Genomadix Bioscience. “He is an excellent addition to our leadership team.”

“Genomadix is leading the way to a diagnostics revolution with their portable DNA testing technology and I am excited to build on their incredible momentum as Chief Revenue Officer,” said Mr. Noreau.

For more information about careers at Genomadix, please visit https://genomadix.com/about-us/careers/.

About Genomadix Bioscience
Genomadix Bioscience is the leader in on-demand DNA testing.(1) Genomadix’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. The Genomadix Cube, the world’s smallest DNA analyzer, enables unprecedented portability and convenience in applications such as infectious disease, pharmacogenetics, and food and water safety testing. For more information, please visit https://spartanbio.forcefivedev.ca.

  1. Roberts JD et al. (2012). Lancet. 379:1705–11.

Discover More Articles

Which Test Are You Looking For?